Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Feb 9, 2016

Sanofi Delivered 2015 Business EPS up 8.5% on a Reported Basis and Stable at Constant Exchange Rates Consistent with Guidance
- Photos 1
Feb 2, 2016

Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association

Study Evaluated Adult Patients with Chronic Sinusitis with Nasal Polyposis who did not Respond to Intranasal Corticosteroids
Feb 2, 2016

American Diabetes Association Announces Research Grant Award Recipients

Six researchers each receive $1.625 million in "Pathway to Stop Diabetes®" awards
Feb 1, 2016

Merial Appoints Susan Sholtis as President, North America
- Photos 1
Jan 28, 2016

Merial Collaborates with Georgia Institute of Technology to Bring Animal Health Information to Connected Devices

- Aims to advance animal health though internet-connected technology and networks -
- Photos 1
Jan 8, 2016

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA
Dec 23, 2015

Sanofi Submits New Drug Application for the Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
Dec 18, 2015

Sanofi Pasteur “Adopts” Families Who Have Little to Call Their Own

Record-breaking holiday gift drive responds to increased homelessness rates
Dec 11, 2015

Sanofi and Regeneron Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection for Preferred Access

Praluent® is the only PCSK9 inhibitor preferred across UnitedHealth Group formularies, including OptumRx and UnitedHealthcare Commercial, Medicare, and Managed Medicaid formularies
Dec 1, 2015

Sanofi Launches New Priftin® (Rifapentine) Packaging

New 24 and 32-Packs Designed to Manage Dosage Regimens for both Latent and Active Tuberculosis
- Photos 1

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.